Our enteric-coated capsules protect active ingredients from stomach acid, ensuring direct nutrient delivery to the intestines for maximum bioavailability and absorption
Projections of approvals in the AOM space will be priced at a premium if these medications prove to have an advantage in either safety or efficacy against established AOMs such as Wegovy and Saxenda
No FDA-approved drug product containing ipamorelin has been identified (Drugs@FDA, 2026-05-09 search)
Here we review the nutrient-sensing mechanisms that control the secretion of four of these hormones, ghrelin, cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide tyrosine tyrosine [PYY(336)], and their contributions to the controls of GI motor function, food intake, and meal-related increases in glycemia in healthy-weight and obese persons, as well as in RYGB patients
Request comprehensive metabolic panels every three to six months during treatment and every one to three months during and after tapering